Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study

Abstract

The outcomes of acquired TTP treated with S/D plasma or qFFP seem similar and therefore both preparations can be used safely for PE in this indication. The faster response of S/D plasma observed in younger patients warrants confirmation in prospective studies.

Characterization of efficacy and safety of pathogen inactivated and quarantine plasma in routine use for treatment of acquired immune thrombotic thrombocytopenic purpura

“…Cardiac adverse events were the antecedent cause of death in only one QP patient (nodal rhythm, bradycardia and cardiac arrest). Mortality was not substantially different from that reported in other studies .…”

“…The size of the study population was limited by the low frequency of auto‐immune TTP. Both types of plasma provided remission rates consistent with those reported for primary idiopathic TTP with conventional plasma . Multiple secondary efficacy outcomes were similar between treatment groups.…”

“…The recent retrospective study of Toussaint‐Hacquard et al . compared two types of plasma for TPE of TTP, but did not report cardiac findings.…”

“…Multiple secondary efficacy outcomes were similar between treatment groups. The median time to remission at day 60 was shorter for IBSP compared to QP; but this may have been due to use of larger volumes of plasma for TPE due to practice evolution in later years as reported in other studies .…”

Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

“…Pooling has the added benefit of diluting allergens by approximately 1000‐fold, which reduces the risk of allergic reactions. Multiple studies have shown a comparative reduction in the rate of allergic reactions (Table ) . Pooling likely mitigates the risk of TRALI by diluting and neutralizing antibodies to human neutrophil antigen and HLA.…”